Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
3 reports, 2 independent
Updated Fri 00:00
No new developments lately
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Evaxion presented data at the ESMO Congress in Madrid.1 source
Evaxion to present data on MSD's anti-PD-1 therapy at ESMO in Berlin.1 source
Keep exploring
The entities involved
-
Merck KGaA
German multinational science and technology company
-
Merck Sharp & Dohme
company in Madrid, Spain
Nothing else this week.
-
European Society for Medical Oncology
Professional organisation
Related events
- AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- Hengrui Pharma and Guangdong Provincial People's Hospital presented research findings at the ESMO Congress on October 20, 2026.
- Pliant Therapeutics announced its presentation at the European Society for Medical Oncology (ESMO) Congress on October 1, 2026.
- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- GlobeNewswireEvaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (N